| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10148669 | Clinical Immunology | 2018 | 22 Pages |
Abstract
TNFα-antagonists are safe and might be associated with a decreased risk of relapse at 9â¯months compared to conventional immunosuppressants in BD patients with major vessels disease.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
A.C. Desbois, L. Biard, O. Addimanda, M. Lambert, E. Hachulla, D. Launay, F. Ackermann, L. Pérard, A. Hot, F. Maurier, C. Mausservey, F. Bernard, N. Noel, L. Alric, T. Mirault, F. Cohen, S. Boussouar, M. Resche-Rigon, D. Saadoun,